Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a type of medication used to treat type 2 diabetes. It was developed by Novo Nordisk and approved by the U.S. Food and Drug Administration (FDA) in December 2017. It is the first once-weekly GLP-1 receptor agonist available in the United States. Semaglutide works by stimulating the release of insulin in response to elevated blood sugar levels. It also reduces appetite and slows the rate of digestion, helping to reduce the amount of glucose entering the bloodstream. Additionally, semaglutide helps the body to use insulin more efficiently. Semaglutide is used in combination with diet and exercise to improve glycemic control in adults. It is also approved for use in combination with other antidiabetic medications, such as metformin, sulfonylureas, and thiazolidinediones. For more information visit us at https://activemedicalgroup.com/weight-loss
